Urovant Sciences Announces U.S. FDA Approval of GEMTESA
Urovant Sciences announced FDA approval of GEMTESA® (vibegron) 75 mg tablets for overactive bladder (OAB) treatment, offering a new option for adults with symptoms like urge urinary incontinence, urgency, and frequency. GEMTESA, a beta-3 agonist, relaxes the bladder muscle, improving symptoms without known cognitive decline risks.
Reference News
Urovant Sciences Announces U.S. FDA Approval of GEMTESA
Urovant Sciences announced FDA approval of GEMTESA® (vibegron) 75 mg tablets for overactive bladder (OAB) treatment, offering a new option for adults with symptoms like urge urinary incontinence, urgency, and frequency. GEMTESA, a beta-3 agonist, relaxes the bladder muscle, improving symptoms without known cognitive decline risks.